1.Metabolic complications of androgen deprivation therapy and its intervention management.
Yong-Hui HU ; Song WU ; Meng ZHANG
National Journal of Andrology 2018;24(3):277-281
Androgen deprivation therapy (ADT) is one of the dominant treatment options for advanced prostate cancer, which has been certified to significantly improve the overall survival of prostate cancer patients. However, it sometimes can also produce severe adverse effects on body metabolism. This review summarizes the adverse effects of ADT on body composition, the levels of cholesterol and blood glucose, and the cardiovascular system, and the intervention management of these metabolic complications as well.
Androgen Antagonists
;
adverse effects
;
Blood Glucose
;
drug effects
;
Body Composition
;
drug effects
;
Cardiovascular System
;
drug effects
;
Cholesterol
;
blood
;
Humans
;
Male
;
Prostatic Neoplasms
;
blood
;
drug therapy
2.Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer.
Yong-Hui HU ; Jian-Chao GUO ; Meng ZHANG
National Journal of Andrology 2017;23(12):1138-1140
Bipolar androgen therapy (BAT), as a new therapeutic strategy for castration-resistant prostate cancer (CRPC), can significantly reduce the level of prostate-specific antigen (PSA) for prostate cancer patients and has exhibited an excellent safety profile with no serious adverse events. Based on the clinical trials recently published at home and abroad, this article reviews the background, action mechanism, development, and prospect of BAT.
Androgen Antagonists
;
therapeutic use
;
Hormone Replacement Therapy
;
methods
;
Humans
;
Male
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms, Castration-Resistant
;
blood
;
drug therapy
;
Receptors, Androgen
;
Testosterone
;
administration & dosage
;
blood
3.A case of metastatic castration-resistant prostate cancer by abiraterone treatment.
Liuxun LI ; Zhi LONG ; Leye HE
Journal of Central South University(Medical Sciences) 2015;40(6):688-692
We reviewed and analyzed the clinical data for a patient with metastatic castration-resistant prostate cancer (mCRPC) from September, 2009 to December, 2014. After the treatment with abiraterone, patient's performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. tPSA or fPSA fluctuated between
30 and 50 ng/mL or between 10 and 20 ng/mL. MRI showed the left peripheral zone reduced. MRI and bone single photon emission computed tomography (SPECT) scan showed no new metastasis. These results indicated that application of abiraterone for patient with mCRPC not only decreased prostate specific antigen (PSA) levels and tumor volume, but also blocked bone metastasis progression and enhanced pain relief.
Androstenes
;
therapeutic use
;
Bone Neoplasms
;
drug therapy
;
secondary
;
Disease Progression
;
Humans
;
Male
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms, Castration-Resistant
;
drug therapy
;
pathology
4.Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population.
Xin ZHANG ; Yong YANG ; Qi WANG
Chinese Medical Journal 2014;127(11):2143-2146
BACKGROUNDEpidemiological studies have shown that lycopene has anti-prostate cancer effect. In vitro tests also confirmed that it can promote apoptosis of prostate cancer cells. We investigated the effect of whole-tomato supplement lycopene on the prostate-specific antigen velocity in selected prostate cancer patients.
METHODSTwenty selected prostate cancer patients were given whole-tomato supplement lycopene 10 mg per day for about 6 months. Blood samples of patients were collected weekly to measure serum prostate-specific antigen (PSA) values. PSA velocity slope, which reflects the change of PSA, and the degree of change were also calculated. By comparing the values of average PSA velocity slope (rise or fall of PSA) before and after the administration of lycopene, the effect of lycopene can be evaluated. Blood chemistry analysis was regular followed as safety control.
RESULTSThree patients in the research group withdrew within 3 weeks because of inability to conform. The rest 17 patients continued for an average period of 6 months. Two patients withdrew because of cancer progression (PSA rise) who later received active treatment. The average fall in PSA was equivalent to 2.56% over (i.e. an average slope/d of -0.000 28) the first 3 months. In the last 3 months, average fall in PSA was equivalent to 31.58% (i.e. an average slope/d of -0.003 51). The Wilcoxon rank-sum test showed a statistically significant decrease of PSA velocity slope overall (P = 0.000 9). Analysis of the PSA doubling time (pre- vs. post-treatment) showed a median increase over 3 months but this was not statistically significant (P = 0.21). No toxic side effect was observed during the whole process. The results indicate that the average PSA change is "decline" in patients, and the degree of the decline is accelerated.
CONCLUSIONAdministration of lycopene was able to reduce PSA velocity in this study group.
Aged ; Carotenoids ; therapeutic use ; Dietary Supplements ; Female ; Humans ; Male ; Prostate-Specific Antigen ; metabolism ; Prostatic Neoplasms ; blood ; drug therapy
5.Significance of Neoadjuvant Hormonal Therapy in Radical Retropubic Prostatectomy: A Retrospective Single-Surgeon Study.
Fukashi YAMAMICHI ; Katsumi SHIGEMURA ; Shinichi MORISHITA ; Kunito YAMANAKA ; Kazushi TANAKA ; Hideaki MIYAKE ; Masato FUJISAWA
Yonsei Medical Journal 2013;54(2):410-415
PURPOSE: The purpose of this study was to evaluate whether neo-adjuvant hormonal therapy (NHT) prior to radical retropubic prostatectomy (RRP) for prostate cancer (PCa) is beneficial in terms of surgical outcomes and for preventing or delaying biochemical recurrence via single-surgeon case series study. MATERIALS AND METHODS: Fifty-three men underwent RRP by a single surgeon. The patients were divided into two groups according to whether or not NHT was performed prior to RRP. The study was analyzed retrospectively. We evaluated clinical parameters, surgical parameters, and biochemical recurrence rate. Group 1 (n=34) was treated with RRP only, while Group 2 (n=19) underwent RRP along with NHT. RESULTS: There were no significant differences in clinical, operation-related and pathological factors between the two groups (p>0.05). There was also no significant difference in biochemical recurrence rate between the two groups at the last follow-up, although Group 2 tended to have a lower PCa recurrence rate than Group 1 and the initial prostate-specific antigen (PSA) level was significantly higher in Group 2 than Group 1 (p=0.0496). CONCLUSION: The present single-surgeon case series study revealed a trend toward a lower rate of PCa recurrence in NHT+RRP treated patients compared to those treated with RRP alone, but this did not reach statistical significance, despite the fact that NHT+RRP patients exhibited higher serum PSA levels preoperatively. Prospective studies with a longer duration of observation and a greater number of patients would be helpful in evaluating NHT more definitively.
Humans
;
Kallikreins/blood
;
Male
;
*Neoadjuvant Therapy
;
Preoperative Period
;
Prostate-Specific Antigen/blood
;
*Prostatectomy
;
Prostatic Neoplasms/*drug therapy/surgery
;
Recurrence
;
Retrospective Studies
6.Metabolic syndrome and androgen deprivation therapy in metabolic complications of prostate cancer patients.
Jia-Qi YUAN ; Tao XU ; Xiao-Wei ZHANG ; Lu-Ping YU ; Qing LI ; Shi-Jun LIU ; Xiao-Bo HUANG ; Xiao-Feng WANG
Chinese Medical Journal 2012;125(20):3725-3729
BACKGROUNDIncidence of prostate cancer in Chinese males grows significantly in the past decades. Androgen deprivation therapy has been generally employed in the treatment of locally advanced and metastatic prostate cancer for many years, yet only little data was known about the metabolic syndrome in patients receiving hormonal therapy. This study described the prevalence and the changing trends of hormone-related metabolic complications, and analyzed their correlation with different therapies.
METHODSIn 125 patients treated with castration or maximal androgen blockage for at least 12 months, metabolic indicators were analyzed.
RESULTSTotally, 13.5% patients in castration group and 30.1% patients in maximal androgen blockage group were diagnosed metabolic syndrome 12 months after the beginning of treatments (χ(2) = 4.739, P = 0.029). In castration group, increased triglyceride and decreased high-density lipoprotein-cholesterol were significant at the month 12, increased fasting plasma glucose and blood pressure were significant at the month 4. In maximal androgen blockage group, increased triglyceride and decreased high-density lipoprotein-cholesterol were significant at the month 4, increased fasting plasma glucose and blood pressure were significant at the month 8. Total testosterone and free testosterone in maximal androgen blockage group were significantly lower than castration group at all visits, which were proved to show positive or negative correlations with metabolic indications. Severity of metabolic complications in maximal androgen blockage group was generally more serious than people received castration, with significantly statistical difference or not. Trends of high-density lipoprotein-cholesterol and fasting plasma glucose were significant different between two kinds of therapy (P = 0.005, P = 0.019, respectively).
CONCLUSIONSProstate cancer patients receiving androgen deprivation therapy were at high risk of suffering metabolic syndrome. Severity of metabolic complications under different hormonal therapies were not completely consistent, suggested that androgen deprivation therapy may be individualized.
Adult ; Aged ; Androgen Antagonists ; therapeutic use ; Blood Glucose ; analysis ; Cholesterol, HDL ; blood ; Humans ; Male ; Metabolic Syndrome ; etiology ; Middle Aged ; Neoplasm Grading ; Orchiectomy ; Prostatic Neoplasms ; complications ; drug therapy ; metabolism
7.Anemia in patients on combined androgen block therapy for prostate cancer.
Li-xin HUA ; Hong-fei WU ; Yuan-geng SUI ; Shuang-guan CHENG ; Zheng-quan XU ; Wei ZHANG
Chinese Journal of Oncology 2003;25(5):496-497
OBJECTIVETo study the effect of combined androgen block therapy on hemoglobin (Hb) and hematocrit value (Ht) in patients with prostate cancer.
METHODSOne hundred and thirty-six patients with adenocarcinoma of the prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, Tid). Complete blood counts were detected before initiation and after 1, 2, 3, 6, 9 and 12 months of therapy.
RESULTSHb level declined significantly in all patients from a mean baseline of (136 +/- 14) g/L to (126 +/- 16) g/L, (121 +/- 14) g/L, (120 +/- 15) g/L, (113 +/- 12) g/L, (121 +/- 13) g/L and (123 +/- 15) g/L at 1, 2, 3, 6, 9 and 12 months. Ht decreased from a mean baseline of 0.424 +/- 0.041 to 0.390 +/- 0.038, 0.381 +/- 0.042, 0.378 +/- 0.038, 0.366 +/- 0.041, 0.384 +/- 0.039 and 0.387 +/- 0.040. The differences between Hb, Ht before and after treatment were significant (P < 0.05).
CONCLUSIONPatients with prostate cancer being treated with combined androgen block would develop a significant degree of anemia. Hemoglobin and hematocrit level should be monitored periodically. This kind of anemia can be treated by recombinant human erythropoietin.
Aged ; Aged, 80 and over ; Androgen Antagonists ; adverse effects ; Anemia ; chemically induced ; Hematocrit ; Hemoglobins ; analysis ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms ; blood ; drug therapy
8.Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer.
Kyo Chul KOO ; Dong Hoon LEE ; Kyu Hyun KIM ; Seung Hwan LEE ; Chang Hee HONG ; Sung Joon HONG ; Byung Ha CHUNG
Yonsei Medical Journal 2014;55(3):570-575
PURPOSE: To evaluate the kinetics of serum testosterone (T) recovery following short-term androgen deprivation therapy (ADT), as the understanding thereof is essential for the proper management of prostate cancer (PCa), especially intermittent ADT. MATERIALS AND METHODS: This prospective analysis included male sex offenders who voluntarily received leuprolide acetate in order to alleviate sexual aberrance. Thirty-three and 25 patients who received 3 and 6 months of ADT were assigned to Group A and Group B, respectively. Serum T levels were obtained every week during the on-cycle period, then monthly during the off-cycle period for at least 12 months. RESULTS: The kinetics of serum T during the on-cycle period were similar in both groups. After flare reaction at week 2, a nadir of 0.45+/-0.29 ng/mL was achieved. In Group A, an abrupt rebound-upsurge was observed during the first 2 month off-cycle period, which surpassed the baseline level and reached a plateau level of 8.74+/-2.11 ng/mL during the flare (p<0.001). This upsurge was followed by a gradual decline back to baseline over the following 10 months. In Group B, a gradual increase was observed, and a baseline level of 7.26+/-1.73 ng/mL was reached at 5 months. Thereafter, an ongoing upsurge that surpassed baseline levels was observed until 12 months (8.81+/-1.92 ng/mL; p=0.002). CONCLUSION: The kinetics of serum T recovery during the off-cycle period varied according to the duration of ADT. Serum T should be monitored beyond normalization, as an excessive rebound may improve quality-of-life, but hamper the treatment efficacy of PCa.
Adult
;
Androgen Antagonists/*therapeutic use
;
Follicle Stimulating Hormone/blood
;
Humans
;
Luteinizing Hormone/blood
;
Male
;
Middle Aged
;
Prospective Studies
;
Prostatic Neoplasms/*blood/*drug therapy
;
Testosterone/*blood
;
Treatment Outcome
;
Young Adult
9.Qilan Capsules plus androgen-deprivation therapy for Qi-deficiency blood-stasis type of prostate cancer after castration.
De-Gui CHANG ; Xiang LI ; Jian-Hua ZOU ; Xu-Jun YU ; Xiao-Fang PAN ; Tian-Lang WU ; Guang-Sen LI ; Wen-Ying CHEN ; Cheng CHEN
National Journal of Andrology 2017;23(7):646-651
Objective:
To observe the synergistic effect of Qilan Capsules in the treatment of the patient with Qi-deficiency blood-stasis type of prostate cancer receiving androgen-deprivation therapy after castration.
METHODS:
This randomized controlled double-blind study included 246 cases of Qi-deficiency blood-stasis type of prostate cancer after castration, which were randomly divided into an experiment and a control group of equal number to be treated with Qilan Capsules + androgen-deprivation and placebo + androgen-deprivation, respectively. After 6 months of treatment, we compared the International Prostate Symptoms Scores (IPSS), TCM Symptoms Scores (TCMSS), maximal urine flow rate (Qmax), and the level of serum prostate-specific antigen (PSA) between the two groups of patients.
RESULTS:
Statistically significant differences were observed between the experiment and control groups in the syndrome classification-based efficacy (87.7% vs 67.9%, P <0.05) and total effectiveness rate (86.0% vs 71.6%, P <0.05). Compared with the baseline, the experiment group showed remarkable improvement after treatment in TCMSS (17.1±5.1 vs 8.3±4.0, P <0.05), IPSS (17.7±7.5 vs 11.4±4.6, P <0.05), and Qmax ([10.9±4.3] ml/s vs [14.7±3.7] ml/s, P <0.05), and so did the control group (16.8±5.2 vs 11.5±5.2, 17.8±6.7 vs 14.6±5.8, and [11.0±4.3] ml/s vs [12.0±4.1] ml/s, P <0.05). The above three parameters were even more markedly improved in the former than in the latter group (P <0.05). However, there was no statistically significant difference between the two groups in the improvement of the PSA level after treatment (P >0.05).
CONCLUSIONS
Qilan Capsules can significantly enhance the effect of androgen-deprivation therapy in the treatment of Qi-deficiency blood-stasis type of prostate cancer after castration though cannot obviously improve the PSA level.
Androgen Antagonists
;
therapeutic use
;
Capsules
;
Double-Blind Method
;
Drug Therapy, Combination
;
methods
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Male
;
Orchiectomy
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms
;
blood
;
blood supply
;
surgery
;
Qi
;
Quality of Life
;
Treatment Outcome
10.The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study.
Jung Kwon KIM ; Jung Jun KIM ; Taek Won GANG ; Tae Kyun KWON ; Hong Sup KIM ; Seung Chul PARK ; Jae-Shin PARK ; Jong-Yeon PARK ; Seok Joong YOON ; Youn-Soo JEON ; Jin Seon CHO ; Kwan Joong JOO ; Sung-Hoo HONG ; Seok-Soo BYUN
Asian Journal of Andrology 2019;21(2):115-120
We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were included in this multi-institutional, observational study of prospectively collected data. All luteinizing hormone-releasing hormone (LHRH) agonists were allowed to be investigational drugs. Efficacy was defined as (1) the rate of castration (serum testosterone ≤50 ng dl-1) at 4-week visit and (2) breakthrough (serum testosterone >50 ng dl-1 after castration). Safety assessments included routine examinations for potential adverse events, laboratory tests, blood pressure, body weight, and bone mineral density (BMD, at baseline and at the last follow-up visit). QoL was assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26). The most common initial therapeutic regimen was LHRH agonist with anti-androgen (78.0%), and the most commonly used LHRH agonist for combination and monotherapy was leuprolide (64.0% for combination and 58.0% for monotherapy). The castration and breakthrough rates were 78.4% and 6.6%, respectively. The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment. In addition, the mean BMD T-score was significantly lower at the last follow-up (mean: -1.950) compared to baseline (mean: -0.195). The mean total EPIC-26 score decreased from 84.8 (standard deviation [s.d.]: 12.2) to 78.3 (s.d.: 8.1), with significant deterioration only in the urinary domain (mean: 23.5 at baseline and 21.9 at the 4-week visit). These findings demonstrate the nationwide trend of current practice settings in hormone treatment for PCa in Korea.
Aged
;
Androgen Antagonists/therapeutic use*
;
Antineoplastic Agents, Hormonal/therapeutic use*
;
Cholesterol/blood*
;
Drug Therapy, Combination
;
Humans
;
Leuprolide/therapeutic use*
;
Male
;
Middle Aged
;
Prostatic Neoplasms/pathology*
;
Quality of Life
;
Receptors, LHRH/agonists*
;
Republic of Korea
;
Testosterone/blood*
;
Treatment Outcome
;
Triglycerides/blood*